Genscript Biotech (HKG:1548) returned to an attributable profit of $2.96 billion in 2024, compared with a loss of $95.5 million in the prior year, according to a Wednesday filing with the Hong Kong bourse.
The recovery came as the company booked a $3.2 billion gain from the deconsolidation of its cell therapy business.
Earnings per share were $1.3597, compared with a loss per share of $0.0453 a year ago. Seven visible Alpha analysts expected a loss per share of $0.07.
Revenue for the year rose 6.1% to $594.5 million from $560.5 million in the previous year. Visible Alpha estimated an annual revenue of $574.1 million.
The bioscience firm shares were almost 4% down in recent trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。